- Home
- UPBD vs ETNB Comparison
UPBD vs ETNB Comparison
Compare UPBD & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPBD
- ETNB
- Stock Information
- Founded
- UPBD 1986
- ETNB 2018
- Country
- UPBD United States
- ETNB United States
- Employees
- UPBD N/A
- ETNB N/A
- Industry
- UPBD Diversified Commercial Services
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- UPBD Consumer Discretionary
- ETNB Health Care
- Exchange
- UPBD Nasdaq
- ETNB Nasdaq
- Market Cap
- UPBD 1.5B
- ETNB 1.5B
- IPO Year
- UPBD 1995
- ETNB 2019
- Fundamental
- Price
- UPBD $20.72
- ETNB $9.16
- Analyst Decision
- UPBD Buy
- ETNB Strong Buy
- Analyst Count
- UPBD 4
- ETNB 8
- Target Price
- UPBD $34.50
- ETNB $26.43
- AVG Volume (30 Days)
- UPBD 723.6K
- ETNB 1.3M
- Earning Date
- UPBD 07-31-2025
- ETNB 08-12-2025
- Dividend Yield
- UPBD 7.53%
- ETNB N/A
- EPS Growth
- UPBD 77.94
- ETNB N/A
- EPS
- UPBD 1.79
- ETNB N/A
- Revenue
- UPBD $4,481,986,000.00
- ETNB N/A
- Revenue This Year
- UPBD $10.08
- ETNB N/A
- Revenue Next Year
- UPBD $7.74
- ETNB N/A
- P/E Ratio
- UPBD $11.57
- ETNB N/A
- Revenue Growth
- UPBD 7.49
- ETNB N/A
- 52 Week Low
- UPBD $19.65
- ETNB $4.16
- 52 Week High
- UPBD $38.43
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- UPBD 29.17
- ETNB 37.30
- Support Level
- UPBD $24.56
- ETNB $9.12
- Resistance Level
- UPBD $25.19
- ETNB $9.76
- Average True Range (ATR)
- UPBD 1.22
- ETNB 0.45
- MACD
- UPBD -0.49
- ETNB -0.15
- Stochastic Oscillator
- UPBD 16.03
- ETNB 6.19
About UPBD Upbound Group Inc.
Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has three operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions across e-commerce, digital, and mobile channels, Mexico segment offers lease-to-own stores in Mexico. The franchising segment offers the sale of rental merchandise to its franchisees. The company derives a majority of its revenue from the Acima segment.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).